Ascend Gene & Cell Therapies
Karl Heller is an experienced professional in the biotechnology and biopharmaceutical sectors, currently serving as Site Head, VP CMC Development, and Managing Director at Ascend Advanced Therapies since February 2023. Previously, Karl held various leadership roles, including Managing Director and VP CMC Development at Freeline from June 2019 to February 2023, and Senior Consultant at Biopharma Excellence from July 2018 to May 2019. Karl's extensive career includes positions such as Senior Expert Technical Operations at IDT Biologika and Managing Director at Emergent Product Development Germany GmbH and Emergent Sales & Marketing Germany GmbH. Additionally, Karl has held multiple senior director roles at Emergent BioSolutions and served as CEO of VIVACS GmbH. Karl's educational background includes a Dipl. Ing. (FH) in Biotechnology from Berlin University of Applied Sciences and a CTA in Chemistry from Chemieschule Dr. Elhardt, among other academic achievements.
This person is not in any offices
Ascend Gene & Cell Therapies
Ascend Gene & Cell Therapies supports manufacturing and process development projects from design through to clinical and commercial scales. They partner with biotechnology teams to embed scalable manufacturing in their operations from the beginning. They respond to customer inquiries by phone and contact form.